Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM Frontline treatment of elderly non transplant-eligible MM patients using cyclophosphamide, bortezomib, dexamethasone Download here: Multiple Myeloma Research Review Issue 33Continue Reading
A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a study reported. This therapy targets a protein called CD229, produced on the surface of both myeloma cells and cancer stem cells — the source of treatment-resistant cells that may lead to disease recurrence — potentially...Continue Reading
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing organ dysfunction, including in the heart and kidney. Daratumumab, a CD38-targeted antibody, has recently demonstrated efficacy in producing hematologic responses in previously treated disease. However, data on survival outcomes and organ responses to daratumumab are...Continue Reading
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab when measuring levels of monoclonal protein — a marker of disease severity — in a person’s blood. Myeloma is a cancer of plasma cells, the type of cell responsible for making...Continue Reading
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP) halved the risk of disease progression or death, compared with VMP alone, according to updated results from the phase III ALCYONE trial. The findings, which were published in The Lancet, also point...Continue Reading
Mark Wellington cherished the final years he spent with his wife after she was diagnosed with multiple myeloma. Now he wants Pharmac to make good on its promise to fund for others one of the drugs which extended her life. Mark’s wife, Jocelyn, died last month, aged 69, four years after being diagnosed with the...Continue Reading
Happy New Year to everybody. It was a very busy and productive year in 2019. Thanks to everyone who has contributed in so many different ways. The main event for 2019 was the launch of the Myeloma Burden of Disease report at the Parliamentary breakfast. Follow this link for details. A plethora of ideas came...Continue Reading
Results from a new study at Hutchinson Cancer Research Cancer in Seattle suggests that chimeric antigen receptor (CAR) T-cell therapy can be further improved for multiple myeloma. The approach relies on a class of drugs known as gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer disease but were never approved for...Continue Reading
The Prime Minister has acknowledged Blair Vining’s “tireless advocacy” as the new independent Cancer Control Agency was formally opened on Tuesday. During Vining’s final months, as he was dying from cancer, the Southlander pushed for the Government to set up an independent cancer agency to improve cancer care for New Zealanders. In September, a matter of weeks before Vining died,...Continue Reading
Starting Saturday, December 7, HemOnc Today will be onsite in Orlando at the ASH Annual Meeting and Exposition, bringing the latest in important, novel hematology research to our daily feed, with a special focus on multiple myeloma. HemOnc Today spoke with Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center,...Continue Reading
